Connect Biopharma Holdings Ltd. (CNTB), a clinical-stage pharmaceutical company, announced on Thursday that it would be proceeding with enrolment for the Phase 2 Seabreeze STAT trial for Rademikibart in treating asthma and COPD, following a review by the independent data monitoring committee.
Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Ra). By blocking the T-helper 2 (Th2) inflammatory pathway, it can treat Th2 inflammatory diseases like atopic dermatitis, asthma, and chronic obstructive pulmonary disorder (COPD).
The independent data monitoring committee reviewed data based on a pre-specified interim analysis of efficacy and reported no safety concerns. The interim review came after treatment of a minimum of 50 patients, and at least 28 days of follow-up.
The company plans to release topline data by mid-2026 and will align with the U.S. Food and Drug Administration (FDA) on the Phase 3 clinical trial.
CNTB closed Thursday's trading at
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.